FR2965178B1 - Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer - Google Patents

Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer

Info

Publication number
FR2965178B1
FR2965178B1 FR1003859A FR1003859A FR2965178B1 FR 2965178 B1 FR2965178 B1 FR 2965178B1 FR 1003859 A FR1003859 A FR 1003859A FR 1003859 A FR1003859 A FR 1003859A FR 2965178 B1 FR2965178 B1 FR 2965178B1
Authority
FR
France
Prior art keywords
alzheimer
disease
treatment
pharmaceutical composition
composition used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1003859A
Other languages
English (en)
Other versions
FR2965178A1 (fr
Inventor
Sebastien Lasnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR1003859A priority Critical patent/FR2965178B1/fr
Priority to PCT/FR2011/000528 priority patent/WO2012042128A1/fr
Publication of FR2965178A1 publication Critical patent/FR2965178A1/fr
Application granted granted Critical
Publication of FR2965178B1 publication Critical patent/FR2965178B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR1003859A 2010-09-29 2010-09-29 Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer Active FR2965178B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1003859A FR2965178B1 (fr) 2010-09-29 2010-09-29 Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer
PCT/FR2011/000528 WO2012042128A1 (fr) 2010-09-29 2011-09-27 Composition pharmaceutique comprenant de la memantine et de la vitamine d pour le traitement de la maladie d 1 alzheimer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1003859A FR2965178B1 (fr) 2010-09-29 2010-09-29 Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
FR2965178A1 FR2965178A1 (fr) 2012-03-30
FR2965178B1 true FR2965178B1 (fr) 2012-10-05

Family

ID=43304969

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1003859A Active FR2965178B1 (fr) 2010-09-29 2010-09-29 Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer

Country Status (2)

Country Link
FR (1) FR2965178B1 (fr)
WO (1) WO2012042128A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3161107A1 (fr) 2024-04-16 2025-10-17 Synaptys Neuroscience Compositions contenant une combinaison synergique de mémantine et de vitamine D

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
IL110309A0 (en) * 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3161107A1 (fr) 2024-04-16 2025-10-17 Synaptys Neuroscience Compositions contenant une combinaison synergique de mémantine et de vitamine D
WO2025219389A1 (fr) 2024-04-16 2025-10-23 Synaptys Neuroscience Compositions contenant une combinaison synergique de mémantine et de vitamine d

Also Published As

Publication number Publication date
WO2012042128A1 (fr) 2012-04-05
FR2965178A1 (fr) 2012-03-30

Similar Documents

Publication Publication Date Title
FR25C1043I1 (fr) Utilisation de citrate ferrique dans le traitement de patients atteints d'une maladie rénale chronique
EP2683382A4 (fr) Régimes posologiques pour le traitement de la maladie de fabry
EP2665479A4 (fr) Procédés et produits médicamenteux destinés au traitement de la maladie d'alzheimer
IL255752B (en) Compounds, pharmaceutical compositions comprising the same and uses thereof for treating cardiovasclar disease, an inflammatory disease or cancer
EP2753348A4 (fr) Composition pharmaceutique utilisée dans le traitement du cancer, comprenant un conjugué de l'interféron alpha
EP2911664A4 (fr) Polythérapies pour le traitement de la maladie d'alzheimer et des troubles associés
EP2542255A4 (fr) Méthodes et compositions pour le traitement de la maladie de degos
EP2486060A4 (fr) Anticorps anti-siglec 15 dans le traitement de maladies liées à une perte osseuse
EP2536425A4 (fr) Vaccins destinés à être utilisés pour la prophylaxie et le traitement d'une maladie liée au virus de la grippe
IL237369A0 (en) Methods for treating Alzheimer's disease and pharmaceutical compositions thereof
EP2622105A4 (fr) Compositions et procédés utiles dans le traitement et le diagnostic d'une maladie intestinale inflammatoire
EP2651407A4 (fr) 3-méthanesulfonylpropionitrile pour le traitement d'une inflammation et de la douleur
EP2552417A4 (fr) Formulations pharmaceutiques pour le traitement de vessie hyperactive
IL234101B (en) Compositions comprising acamprosate and baclofen for use in the treatment of parkinsonism
EP2978446A4 (fr) Procédés et agents pour le traitement de la maladie d'alzheimer
EP2568811A4 (fr) Traitement du tcl et de la maladie d'alzheimer
EP2796142A4 (fr) Composition pharmaceutique comprenant des cellules mortes de la souche lb de lactobacillus acidophilus pour le traitement ou la prévention d'une maladie allergique
IL251543A0 (en) Use of a topical gel composition in the manufacture of a medicament for the prevention or treatment of a skin disorder
EP2642998A4 (fr) Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt
EP2579867A4 (fr) Régime à base de triheptanoïne pour le traitement de la maladie des corps de polyglucosane de l'adulte (apbd)
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
EP2676665A4 (fr) Utilisation de la mangostine- dans la préparation de médicaments destinés à traiter la maladie d'alzheimer
EP2640408A4 (fr) Compositions kératiniques pour le traitement d'une déficience ou lésion osseuse
EP2660600A4 (fr) Médicament de diagnostic et procédé de diagnostic pour la maladie d'alzheimer
EP2910634A4 (fr) Vaccin pour prévenir la maladie de l' dème chez le porc

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16